Cargando…

Safety of seven COVID-19 vaccine booster doses

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661356/ http://dx.doi.org/10.1007/s40278-021-06770-9

Ejemplares similares

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India
por: Du, Zhanwei, et al.
Publicado: (2023)

AEs after homologous versus heterologous COVID-19 booster
Publicado: (2022)

Prevertebral Inflammatory Myofibroblastic Tumor Following COVID Vaccine Booster Dose
por: Sprenger, Flávia, et al.
Publicado: (2023)

COVID-19 vaccine equity and booster doses
por: The Lancet Infectious Diseases
Publicado: (2021)

Safety of mRNA COVID-19 vaccines during pregnancy
Publicado: (2022)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Interim statement on covid-19 vaccine booster doses
Publicado: (2021)

Myopericarditis After COVID-19 Booster Dose Vaccination
por: Sharff, Katie A., et al.
Publicado: (2022)

Immunogenicity and Safety of Homologous Booster Doses of CoronaVac COVID-19 Vaccine in Elderly Individuals Aged 60 Years and Older: A Dosing Interval Study — Yunnan Province, China, 2021–2022
por: Yang, Haitao, et al.
Publicado: (2023)

Safety of COVID-19 booster dose: is the juice worth the squeeze?
por: Madhi, Shabir A, et al.
Publicado: (2023)

Myocarditis after third dose of Pfizer-BioNTech COVID-19 vaccine
Publicado: (2022)

Possible HSP reactivation post‐COVID‐19 vaccination and booster
por: Kondo, Makoto, et al.
Publicado: (2021)

Strategies and safety considerations of booster vaccination in COVID-19
por: Meng, Hanyan, et al.
Publicado: (2022)

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
por: Omma, Ahmet, et al.
Publicado: (2022)

Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink
por: Katherine Yih, W., et al.
Publicado: (2023)

Booster or additional vaccination doses in patients vaccinated against COVID-19
por: García-Botella, Alejandra, et al.
Publicado: (2021)

No safety signal after COVID-19 vaccination for immune-mediated neurological events
Publicado: (2022)

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
por: Rzymski, Piotr, et al.
Publicado: (2021)

Why promoting a COVID-19 vaccine booster dose?
por: Loubet, Paul, et al.
Publicado: (2021)

Efficacy of COVID-19 vaccine booster doses in older people
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

COVID-19 booster doses in pregnancy and global vaccine equity
por: Kalafat, Erkan, et al.
Publicado: (2022)

Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
por: Croda, Julio, et al.
Publicado: (2022)

Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity
por: Abdollahi, Alireza, et al.
Publicado: (2022)

Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly
por: Mattiuzzi, Camilla, et al.
Publicado: (2023)

Assessing the acceptability of COVID‐19 vaccine and its booster dose
por: Mubarak, Sawsan, et al.
Publicado: (2023)

The pros and cons of the second booster dose of the COVID-19 vaccine
por: Mostafavi, Ehsan
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

COVID vaccine booster doses for omicron variants
por: Burki, Talha
Publicado: (2022)

Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
Publicado: (2022)

Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China
por: Zhou, Hui Jun, et al.
Publicado: (2022)

Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients
por: Pai, Mei-Fen, et al.
Publicado: (2023)

Durability of immune responses to mRNA booster vaccination against COVID-19
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia
por: Harapan, Harapan, et al.
Publicado: (2022)

COVID-19 Vaccine Booster Dose Acceptance among Older Adults
por: Sezerol, Mehmet Akif, et al.
Publicado: (2023)

Investigating the tendency to use COVID-19 vaccine booster dose in Iran
por: Askarian, Mehrdad, et al.
Publicado: (2023)

COVID-10 vaccine safety monitoring in US: no serious concerns
Publicado: (2021)

Updated report of COVID-19 vaccine safety monitoring in Japan: booster doses for Omicron variants and vaccinations for infants and young children
por: Yamaguchi, Toshihiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qdcacdgjmfa2lopk6notbsvk37